All News
Medication adherence is a problem
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects).
This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
Does Evusheld shield people living with rheumatic diseases?
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Read Article
Potential new treatment for Sjogren's
Is there finally something new on the horizon in Sjogren’s syndrome?
Read Article
Another poster from my research group!
Investigated recommendations in ACR/EULAR guidelines
<1/6th informed by head 2 head RCT
We need more comparative effectivness research!
#ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
Mike Putman EBRheum ( View Tweet)
Katz @GuyKatzMD et al. Coronary involvement in IgG4-RD. 13 cases, all male, median 11 years disease. All elevated serum IgG4. Aneurysms 8/13, arteritis 9/13 periarteritis 11/13. @RheumNow #ACR22 Abstr#1571 https://t.co/At7Gw2kRUp https://t.co/zcXc6oUS0f
Richard Conway RichardPAConway ( View Tweet)
BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Dr. Rachel Tate uptoTate ( View Tweet)
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Richard Conway RichardPAConway ( View Tweet)
Congenital ❤️ Block in Ro/La pregnancies
Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all on 1st echo
👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone
🔥Key messages🔥
🤰serial echo should start @ 16-18wk gestation
👶 early detection ⬆️ outcomes
#ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO
#ACR22 @RheumNow
(credit: as heard by @drceowen) https://t.co/w88peUd4j1
David Liew drdavidliew ( View Tweet)
Mx aging rheumatic dx pt
🌟5M approach🌟
🧠Mind (mood/cog)
💊 Medication (polypharm)
🏃 Mobility
👉Multicomplexity (biopsychsoc)
💪🏻 Matters (aligning 2 specific goals)
💥Interdisciplinary💥
#GeriRheum #ACR22 @RheumNow @B_Buehring_MD @UnaMakris
Patricia Harkins DrTrishHarkins ( View Tweet)
DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS
Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain)
Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited
#ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Mike Putman EBRheum ( View Tweet)
@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis.
Certain HLA haplotypes more linked with autoimmune diseases are present.
#ACR
@RheumNow
Fabio Torres FabioTorressav ( View Tweet)
Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Jack Cush discusses uptake of #telemedicine in 2020 and the relative decline of uptake since then:
@RheumNow -- What's your take on continuing to use #telehealth for rheum visits? #ACR22 https://t.co/OB5Wnnq6Fh
CreakyJoints.org CreakyJoints ( View Tweet)
“Go digital or go home” -- Dr Jack Cush says on #telemedicine in a session at #ACR22 @RheumNow https://t.co/4PzGgS900t
CreakyJoints.org CreakyJoints ( View Tweet)
Dr. Megan Clowse gives 2 major tips on how rheumatologists can help avoid catastrophic pregnancies:
✳️Routinely ask open-ended Qs to promote HONEST dialogue about repro health
✳️Provide ACCURATE info & guidance using discussion guides and handouts
#ACR22 @RheumNow @rheumarhyme https://t.co/qXwKMdJmR8
sheila RHEUMarampa ( View Tweet)
Advancing Telemedicine in Rheumatology
'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
